Product Description

Clinical Monograph: Melsmon (Human Placenta Extract)

1. Classification and Chemical Overview

• Active Composition: Aqueous hydrolysate extracted from healthy human placentas. Each 2 mL ampoule typically contains 100 mg of human placental extract, alongside amino acids, low-molecular-weight peptides, nucleic acid components, vitamins, minerals, and growth factors.

• Therapeutic Class: Biogenic tissue stimulant / Placental therapeutic agent.

• Regulatory Status: Approved as a ethical pharmaceutical drug in countries like Japan (since 1956) and South Korea, where it is prescribed for specific clinical indications or utilized off-label for anti-aging and wellness. Regulated strictly as a Prescription Only Medicine (POM).

2. Mechanism of Action and Pharmacodynamics

• Cellular Regeneration & Biostimulation: The constituent growth factors (such as epidermal growth factor and fibroblast growth factor) and amino acids stimulate fibroblast proliferation, tissue repair, and extracellular matrix synthesis.

• Endocrine & Autonomic Modulation: Acts on hypothalamic-pituitary axes to help stabilize autonomic nervous system dysregulation, frequently dampening vasomotor instability (hot flashes, night sweats) associated with the climacteric period.

• Anti-Inflammatory & Antioxidant Activity: Downregulates pro-inflammatory cytokines and scavenges free radicals, protecting cellular structures from oxidative stress and photo-aging.

3. Approved Clinical Indications and Dosing Scope

• Primary Indications:

  • Management of menopausal symptoms and climacteric disturbances (e.g., hot flashes, insomnia, irritability).

  • Alleviation of chronic physical fatigue and functional exhaustion.

• Dosing Regimen & Administration:

  • Typically administered via subcutaneous injection (or occasionally intramuscularly).

  • Standard therapeutic schedules often involve a 2 mL dose administered 2 to 3 times per week over an initial course of several weeks, followed by maintenance regimens tailored to clinical response.

4. Pharmacokinetic Profile

• Systemic Absorption: Rapidly absorbed into the systemic circulation following subcutaneous administration due to the low molecular weight of its hydrolyzed peptide and amino acid components.

• Distribution & Elimination: Bioactive components distribute widely into target tissues to support cellular metabolism. Elimination occurs via standard endogenous protein catabolism and renal excretion.

5. Physiological Effects and Adverse Event Spectrum

Melsmon modulates systemic vitality, cutaneous elasticity, and vascular tone.

Adverse Reaction Profile

• Common ($\ge 1/100$ to $<1/10$): Localized injection site reactions, including transient pain, erythema, swelling, induration, or minor bruising.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Mild localized pruritus, transient low-grade fever, headache, or general malaise/drowsiness post-injection.

• Rare / Severe (<1/1,000): Hypersensitivity reactions, generalized urticaria, or anaphylactoid responses. Due to human biological derivation, theoretical risks of transmitting blood-borne pathogens exist, though rigorous donor screening and thermal/chemical sterilization processing mitigate this.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindications

• Known hypersensitivity to human placental extracts or formulation excipients (such as benzyl alcohol, which is included locally as a mild anesthetic preservative).

• Pregnancy and lactation.

• Known history of estrogen-dependent malignancies, given the theoretical trophic impact of growth factors.

Key Interacting Factors & Warnings

• Blood Donation Restrictions: A major clinical consequence of receiving human placenta-derived injections is a permanent deferral from blood and organ donation in many national health jurisdictions (e.g., Japan, UK, Canada, and parts of Europe) as a precautionary measure against variant Creutzfeldt-Jakob disease (vCJD) and other untracked human pathogen transmissions.

Clinical Precautions and Administration Guidance

• Aseptic Technique: Must be administered by qualified medical professionals using strict aseptic subcutaneous techniques, rotating injection sites to prevent localized tissue induration.

• Patient Counseling: Patients should be explicitly informed regarding blood donation restrictions prior to initiating therapy.